AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22065795 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid collar (TC) used during lateral cephalogram
Number of subjects: 100
Study 22065795 — intervention group
Group type: COMPARATOR
Intervention: No thyroid collar (TC) used during lateral cephalogram
Number of subjects: 100
Study 18261410 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery on the primary tumour
Number of subjects: 0
Study 18261410 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy
Number of subjects: 0
Study 16507032 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional counselling by volunteer bereavement counsellors
Number of subjects: 0
Study 16507032 — intervention group
Group type: COMPARATOR
Intervention: Integrated intervention delivered by carers
Number of subjects: 0
Study 15142026 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (1 set of 4-5 repetitions at 90% of 1RM)
Number of subjects: 19
Study 15142026 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance training (1 set of 10 repetitions at 70% of 1RM)
Number of subjects: 19
Study 15142026 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training (1 set of 15 repetitions at 50% of 1RM)
Number of subjects: 19
Study 15142026 — intervention group
Group type: EXPERIMENTAL
Intervention: Session RPE measurement
Number of subjects: 19
Study 11689034 — intervention group
Group type: EXPERIMENTAL
Intervention: Static color images of animals and vehicles
Number of subjects: 0
Study 11689034 — intervention group
Group type: COMPARATOR
Intervention: Dynamic point-light displays of animals and vehicles
Number of subjects: 0
Study 9204747 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) mRNA levels
Number of subjects: 0
Study 9204747 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromogranin A mRNA levels
Number of subjects: 0
Study 9204747 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH suppressibility
Number of subjects: 0
Study 9204747 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphilic parts of adenomas
Number of subjects: 0
Study 9204747 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sensitivity
Number of subjects: 0
Study 7952683 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable biofeedback devices for treating oral dysphagia
Number of subjects: 0
Study 7952683 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient progress index (PPI)
Number of subjects: 0
Study 3300758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg orally
Number of subjects: 24
Study 3300758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29331703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10mg/day)
Number of subjects: 152
Study 29331703 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20mg/day)
Number of subjects: 152
Study 29331703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 27456339 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pyrethroid insecticide-treated wall lining (ITWL) and universal coverage (UC) of long-lasting insecticidal nets (LLINs)
Number of subjects: 44
Study 27456339 — intervention group
Group type: COMPARATOR
Intervention: Universal coverage (UC) of long-lasting insecticidal nets (LLINs) alone
Number of subjects: 44
Study 24985342 — intervention group
Group type: EXPERIMENTAL
Intervention: Promillekoll app (Group 1)
Number of subjects: 1932
Study 24985342 — intervention group
Group type: EXPERIMENTAL
Intervention: PartyPlanner app (Group 2)
Number of subjects: 1932
Study 24985342 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 1932
Study 21253739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical syringe technique
Number of subjects: 96
Study 21253739 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe technique
Number of subjects: 96
Study 20413026 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 51
Study 20413026 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker switches
Number of subjects: 51
Study 18477494 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination product (diaphragm and gel)
Number of subjects: 117
Study 18477494 — intervention group
Group type: COMPARATOR
Intervention: Single product (gel alone)
Number of subjects: 117
Study 15730346 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily)
Number of subjects: 0
Study 15730346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg daily)
Number of subjects: 0
Study 15730346 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg daily)
Number of subjects: 0
Study 15730346 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (150 mg daily)
Number of subjects: 0
Study 15730346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (1.5 mg daily)
Number of subjects: 0
Study 15730346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12709522 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised smoking cessation intervention including minimal structured counselling (5‐8 minutes), nicotine patches for three months, and three sessions of counselling (2‐3 minutes) over a three month period.
Number of subjects: 217
Study 12709522 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice consisting of short (30 seconds to one minute) sporadic sessions of unstructured medical antismoking advice.
Number of subjects: 217
Study 12709522 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised smoking cessation intervention
Number of subjects: 217
Study 12709522 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 217
Study 11420098 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg, orally)
Number of subjects: 12
Study 11420098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9263613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (200 mg T.I.D. at meals) plus 1 g oral calcium daily
Number of subjects: 149
Study 9263613 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 1 g oral calcium daily
Number of subjects: 149
Study 9263613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone
Number of subjects: 149
Study 8505665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid as tablets (108 mg/d) with iron
Number of subjects: 68
Study 8505665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid as tablets (108 mg/d) without iron
Number of subjects: 68
Study 8505665 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange segments or juice
Number of subjects: 68
Study 8505665 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw broccoli
Number of subjects: 68
Study 8505665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked broccoli
Number of subjects: 68
Study 8505665 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ascorbic acid
Number of subjects: 68
Study 3442946 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% ethanol administered via nasogastric tube until the 5th postoperative day
Number of subjects: 16
Study 3442946 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alcohol administration)
Number of subjects: 16
Study 3442946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (alcohol and control)
Number of subjects: 16
Study 31009598 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 63
Study 31009598 — intervention group
Group type: COMPARATOR
Intervention: Traditional Home Exercise Program (HEP)
Number of subjects: 63
Study 29233157 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief medical student-delivered cessation intervention
Number of subjects: 67
Study 29233157 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study 25460174 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide infusion during provocative testing
Number of subjects: 59
Study 25460174 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide infusion
Number of subjects: 59
Study 23414697 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I graduated elastic compression stockings (18-21 mm Hg)
Number of subjects: 34
Study 23414697 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II graduated elastic compression stockings (23-32 mm Hg)
Number of subjects: 34
Study 23414697 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (both classes)
Number of subjects: 34
Study 21123667 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dye tape (LDT)
Number of subjects: 30
Study 21123667 — intervention group
Group type: COMPARATOR
Intervention: Medial arch support (MAS)
Number of subjects: 30
Study 19901496 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-foot reflexology (performed three times a week for 6 weeks for 40 min at each session)
Number of subjects: 59
Study 19901496 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study 17110590 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC = 5 mg min/ml) on day 1 plus gemcitabine (1000 mg/m2) on days 1 and 8 for six cycles
Number of subjects: 147
Study 17110590 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC = 5 mg min/ml) on day 1 plus gemcitabine (1000 mg/m2) for three cycles followed by docetaxel (40 mg/m2) on days 1 and 8 plus gemcitabine (1250 mg/m2) on days 1 and 8 for three cycles (B)
Number of subjects: 147
Study 17110590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (130 mg/m2) on day 1 plus gemcitabine (1250 mg/m2) on days 1 and 8 for six cycles (C)
Number of subjects: 147
Study 14764132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin treatment
Number of subjects: 27
Study 14764132 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic microhaematuria)
Number of subjects: 27
Study 11348533 — intervention group
Group type: EXPERIMENTAL
Intervention: melarsoprol treatment
Number of subjects: 588
Study 11326873 — intervention group
Group type: EXPERIMENTAL
Intervention: 2SHRZ/3R2H2Z2
Number of subjects: 366
Study 11326873 — intervention group
Group type: EXPERIMENTAL
Intervention: 2SHRZ/3L1H2Z2
Number of subjects: 366
Study 11326873 — intervention group
Group type: EXPERIMENTAL
Intervention: 2S3H3R3Z3/4L1H2Z2
Number of subjects: 366
Study 11326873 — intervention group
Group type: EXPERIMENTAL
Intervention: 2S3H3R3Z3/4L1H2E2
Number of subjects: 366
Study 8113116 — intervention group
Group type: EXPERIMENTAL
Intervention: External drainage followed by radiation treatment (including intraluminal brachytherapy with Ir-192) in Group II (9 patients)
Number of subjects: 20
Study 8113116 — intervention group
Group type: COMPARATOR
Intervention: External drainage alone in Group I (11 patients)
Number of subjects: 20
Study 3141643 — intervention group
Group type: EXPERIMENTAL
Intervention: Unweighted polyurethane feeding tube
Number of subjects: 0
Study 3141643 — intervention group
Group type: COMPARATOR
Intervention: Weighted polyurethane feeding tube
Number of subjects: 0
Study 3141643 — intervention group
Group type: COMPARATOR
Intervention: Three tube designs (including weighted and unweighted)
Number of subjects: 0
Study 29125325 — intervention group
Group type: EXPERIMENTAL
Intervention: DTC television ads for branded prescription drugs
Number of subjects: 68
Study 28559269 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin at 10 mg/kg/day
Number of subjects: 180
Study 28559269 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin at 15 mg/kg/day
Number of subjects: 180
Study 28559269 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin at 20 mg/kg/day
Number of subjects: 180
Study 28559269 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arms (all doses)
Number of subjects: 180
Study 26424461 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40
Study 26424461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23743467 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 831
Study 23743467 — intervention group
Group type: COMPARATOR
Intervention: 80% oxygen
Number of subjects: 831
Study 21781337 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted oesophagectomy (transthoracic oesophagectomy with two-field lymphadenectomy and laparoscopic gastric mobilisation)
Number of subjects: 200
Study 21781337 — intervention group
Group type: COMPARATOR
Intervention: Conventional open abdominal approach (same procedure as above)
Number of subjects: 200
Study 21781337 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted oesophagectomy
Number of subjects: 200
Study 21781337 — intervention group
Group type: COMPARATOR
Intervention: Conventional open abdominal approach
Number of subjects: 200
Study 19713070 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.15mg/kg subcutaneously every other day for two weeks
Number of subjects: 133
Study 19713070 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.15mg/kg
Number of subjects: 133
Study 19713070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 16454842 — intervention group
Group type: EXPERIMENTAL
Intervention: ePFT
Number of subjects: 12
Study 16454842 — intervention group
Group type: COMPARATOR
Intervention: DT
Number of subjects: 12
Study 15242015 — intervention group
Group type: EXPERIMENTAL
Intervention: Natto intake three times per week (Group 4)
Number of subjects: 73
Study 15242015 — intervention group
Group type: COMPARATOR
Intervention: Natto intake once per week (Group 3)
Number of subjects: 73
Study 15242015 — intervention group
Group type: COMPARATOR
Intervention: Natto intake once per month (Group 2)
Number of subjects: 73
Study 15242015 — intervention group
Group type: COMPARATOR
Intervention: No intake (Group 1)
Number of subjects: 73
Study 11762555 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat (25 mg orally or 10 mg intravenously)
Number of subjects: 36
Study 9236652 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg mefenamic acid given one hour before hysteroscopy
Number of subjects: 0
Study 9236652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7547097 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg tenidap sodium daily for 22 days
Number of subjects: 24
Study 7547097 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo daily for 22 days
Number of subjects: 24
Study 7547097 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg tenidap sodium
Number of subjects: 24
Study 7547097 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 24
Study 2141313 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg t.i.d.
Number of subjects: 9
Study 2141313 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg t.i.d.
Number of subjects: 9
Study 2141313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg t.i.d.
Number of subjects: 9
Study 2141313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 387047 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (30 patients)
Number of subjects: 59
Study 387047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (29 patients)
Number of subjects: 59
Study 31758734 — intervention group
Group type: EXPERIMENTAL
Intervention: Milkshake with resazurin-based solution PrestoBlue (9% v/v)
Number of subjects: 10
Study 31758734 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 10
Study 31296588 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (800 IU/day for 12 months)
Number of subjects: 210
Study 31296588 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch granules)
Number of subjects: 210
Study 28566743 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 0
Study 25816296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 to 100 mg daily added to insulin treatment
Number of subjects: 0
Study 25816296 — intervention group
Group type: COMPARATOR
Intervention: Continuation of insulin treatment
Number of subjects: 0
Study 25266426 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART initiation at different CD4% and age thresholds
Number of subjects: 371
Study 25266426 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART initiation with 'mild' immunosuppression
Number of subjects: 371
Study 25266426 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART initiation with 'advanced' immunosuppression at age <3 years
Number of subjects: 371
Study 25266426 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART initiation
Number of subjects: 371
Study 22312103 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of preoperative chemotherapy with epirubicin 120 mg/m² and ifosfamide 9 g/m² and granulocyte colony-stimulating factor (arm A)
Number of subjects: 328
Study 22312103 — intervention group
Group type: COMPARATOR
Intervention: Five cycles of chemotherapy (three preoperative and two postoperative) (arm B)
Number of subjects: 328
Study 22312103 — intervention group
Group type: COMPARATOR
Intervention: Comparison of arm A versus arm B
Number of subjects: 328
Study 20186064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl iontophoretic transdermal system
Number of subjects: 0
Study 20186064 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia
Number of subjects: 0
Study 18082873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral self-reported nonadherence estimates
Number of subjects: 63
Study 18082873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral self-reported nonadherence at week 4
Number of subjects: 63
Study 18082873 — intervention group
Group type: EXPERIMENTAL
Intervention: Written self-report of nonadherence at week 12
Number of subjects: 63
Study 16287370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 70% of Vo(2)max
Number of subjects: 10
Study 16287370 — intervention group
Group type: COMPARATOR
Intervention: Squatting at 70% of 1 repetition maximum
Number of subjects: 10
Study 16287370 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting
Number of subjects: 10
Study 16287370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 10
Study 16287370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise modes
Number of subjects: 10
Study 12383573 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure management program delivered by day-hospital (DH)
Number of subjects: 234
Study 12383573 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 234
Study 10102097 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring stretching sessions added to fitness program
Number of subjects: 298
Study 10102097 — intervention group
Group type: COMPARATOR
Intervention: Normal basic training
Number of subjects: 298
Study 8965300 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated antihypertensive treatment
Number of subjects: 2298
Study 8965300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2298
Study 1998451 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen alone
Number of subjects: 30
Study 1998451 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching regimen with baclofen
Number of subjects: 30
Study 1998451 — intervention group
Group type: COMPARATOR
Intervention: Stretching regimen with placebo
Number of subjects: 30
Study 1998451 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 30
Study 6664435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis (BHD)
Number of subjects: 11
Study 6664435 — intervention group
Group type: COMPARATOR
Intervention: Acetate dialysis (AHD)
Number of subjects: 11
Study 31606521 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 108
Study 31606521 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 108
Study 25888653 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and therapeutic patient education
Number of subjects: 45
Study 25888653 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy, therapeutic patient education, and therapeutic exercise protocol
Number of subjects: 45
Study 25888653 — intervention group
Group type: COMPARATOR
Intervention: Control group (manual therapy only)
Number of subjects: 45
Study 23769006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheltered group (SG)
Number of subjects: 89
Study 23769006 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 89
Study 23769006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 21830137 — intervention group
Group type: EXPERIMENTAL
Intervention: Method for extracting BDCPP and DPP metabolites from urine
Number of subjects: 9
Study 19483252 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (n=13,823)
Number of subjects: 55736
Study 19483252 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenders (screening group)
Number of subjects: 55736
Study 19483252 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group, n=41,913)
Number of subjects: 55736
Study 17404830 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief screening instrument for PTSD with a cutoff score of 3 or more
Number of subjects: 6852
Study 15088044 — intervention group
Group type: EXPERIMENTAL
Intervention: Welch Allyn SureSight (WASS) hand‐held autorefractor
Number of subjects: 91
Study 15088044 — intervention group
Group type: COMPARATOR
Intervention: Nidek AR‐820 (NAR)
Number of subjects: 91
Study 15088044 — intervention group
Group type: COMPARATOR
Intervention: Retinoscopic refraction (RR)
Number of subjects: 91
Study 11689583 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% miltefosine solution
Number of subjects: 52
Study 11689583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1303534 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.15 mg/kg)
Number of subjects: 29
Study 1303534 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (2.2 mg/kg)
Number of subjects: 29
Study 1303534 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (morphine and meperidine)
Number of subjects: 29